Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amrobion is a fixed-dose combination of neurotropic B-vitamins, comprising thiamine (Vitamin B1), pyridoxine (Vitamin B6), and cyanocobalamin (Vitamin B12). Manufactured by Amros Pharmaceuticals, a generic pharmaceutical company based in Pakistan, it is primarily indicated for the treatment of vitamin B deficiencies and associated neurological disorders such as peripheral neuropathy, neuritis, and neuralgia. Thiamine acts as an essential cofactor in carbohydrate metabolism and nerve function; pyridoxine is involved in amino acid metabolism and the synthesis of neurotransmitters; and cyanocobalamin is critical for DNA synthesis and the maintenance of the myelin sheath. The product is typically formulated as an injection to ensure rapid absorption and therapeutic efficacy in patients with severe deficiencies or malabsorption issues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiamine + pyridoxine + cyanocobalamin (Amros Pharmaceuticals).